Novogene Global

Novogene specializes in the application of advanced molecular biotechnology and high-performance computing in the research field of life science and human health. Established in March 2011, Novogene strives to become a global leader in providing genetic science services and technology products. Over the past decade, Novogene has grown very fast and established global sequencing labs in Asia, America and Europe, and explored its footprint to over 80 countries and regions across 6 continents with over 6,500 global customers. The partners of Novogene include over 3,500 scientfic research institutions and universities, more than 600 hospitals and over 2,400 pharmaceutical and agricultural enterprises. Currently, Novogene has obtained 294 software copyrights and 69 patents. By December 2022, Novogene has co-published and/or been acknowledged in over 16,000 articles in Science Citation Index, with an accumu-lative impact factor 100,000+. As the leader in genome sequencing, Novogene’s business spans across scientific research for life science, medical research and technology services, storage-building sequencing platform services, gene sequencing, mass spectrometry and bio-information technology support for global research, scientific research institutions, hospitals, pharmaceutical R&D enterprises and agricultural enterprises. 北京诺禾致源科技股份有限公司于2011年3月在北京中关村生命科学园注册成立,专注于开拓前沿分子生物学技术和高性能计算在生命科学研究和人类健康领域的应用,致力于成为全球领先的基因科技产品和服务提供者。企业总部位于北京,在天津、香港、新加坡、美国、英国、荷兰、日本设立了分支机构,建立了通量规模领先的基因测序平台和高性能计算平台,有效地支撑着生命科学研究和医疗健康两大领域对大数据分析和存储的需求。公司业务覆盖全球6大洲约80个国家和地区,服务客户超过6500家,成为基因测序科研服务领域的领先企业。